US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Invesco DB G10 Currency Harvest Fund

25.41

0.0000

Volume:- -

Turnover:- -

Market Cap:7.62M

PE:21.29

High:25.41

Open:25.41

Low:25.41

Close:25.41

52wk High:28.40

52wk Low:24.25

Shares:300.04K

Float Shares:300.04K

Volume Ratio:- -

T/O Rate:- -

Dividend:- -

Dividend Rate:- -

EPS(TTM):1.19

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

DBV Technologies Is Maintained at Market Outperform by JMP Securities

DBV Technologies Q1 EPS $(0.26) Up From $(0.28) YoY

DBV Technologies Reports First Quarter 2025 Financial Results

Why DBV Technologies S.A. (DBVT) is Surging in 2025

DBV Technologies announces filing of 2024 Annual Report on Form 10-K and Universal Registration Document

DBV Technologies Delays 10-K Filing Amid Financing Efforts

DBV Technologies Secures $306.9M for Viaskin Peanut Program

DBV Technologies ADRs Rise After Up to $306.9M in New Financing

DBV Technologies Unveils Peanut Allergy Patch Funding of Up to $306.9 Million; Shares Jump Premarket

MT Newswires Live

DBV Technologies Announces Financing of up to $306.9 Million (€284.5 Million) to Advance Viaskin® Peanut Patch Through Biologics License Application Submission and U.S. Commercial Launch, if Approved

DBV Technologies Shares Fall After 2024 Loss Widens

MT Newswires Live

DBV's ADRs Fall After Going-Concern Warning as Cash Dries Up

DBV Technologies' Peanut Allergy Patch Clears FDA Safety Hurdle for Children

MT Newswires Live

DBV Technologies Secures Agreement with FDA on Safety Exposure Data Required for BLA for Viaskin® Peanut Patch in 4–7-year-olds, Accelerating the Timeline for a BLA Filing Submission to 1H 2026, & Reports 2024 Unaudited Financial Results...

DBV Technologies Price Target Maintained With a $10.00/Share by Citizens Capital Markets

DBV Technologies to Participate in Upcoming AAAAI/WAO Joint Congress

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/DBV/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"DBV","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"DBV\",,,,,undefined,":{"symbol":"DBV","market":"US","secType":"STK","nameCN":"Invesco DB G10 Currency Harvest Fund","latestPrice":25.41,"timestamp":1729886400000,"preClose":25.41,"halted":0,"volume":0,"delay":0,"floatShares":300040,"shares":300040,"eps":1.1933,"marketStatus":"Closed Labor Day","change":0,"latestTime":"10-25 16:00:00 EDT","open":25.41,"high":25.41,"low":25.41,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":1.1933,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1756800000000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":25.41,"sharesOutstanding":300040,"nav":25.701,"aum":7711306.3,"bidAskSpread":0.018526,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"DBV\",,,,,undefined,":{"symbol":"DBV","floatShares":300040,"roa":"--","roe":"--","lyrEps":0,"shares":300040,"dividePrice":0,"high":25.41,"amplitude":0,"preClose":25.41,"low":25.41,"week52Low":24.25,"pbRate":"--","week52High":28.4,"institutionHeld":0,"latestPrice":25.41,"eps":1.1933,"divideRate":0,"volume":0,"delay":0,"ttmEps":1.1933,"open":25.41,"prevYearClose":25.2418},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/DBV\",params:#limit:5,,,undefined,":[{"market":"US","date":"2023-03-06","symbol":"DBV","reason":null,"defaultRemindTime":1678113000000,"announcedDate":"2023-01-24","type":"delisting","dateTimestamp":1678078800000},{"market":"US","date":"2022-12-19","symbol":"DBV","amount":0.19276,"defaultRemindTime":1671460200000,"name":"Invesco DB G10 Currency Harvest Fund","recordDate":"2022-12-23","payableDate":"2022-12-20","currency":"USD","type":"dividend","dateTimestamp":1671426000000},{"market":"US","date":"2019-12-23","symbol":"DBV","amount":0.3445,"name":"PowerShares DB G10 Currency Harv","recordDate":"2019-12-31","payableDate":"2019-12-24","currency":"USD","type":"dividend","dateTimestamp":1577077200000}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"DBV\",market:\"US\",,,undefined,":[{"executeDate":"2019-12-23","recordDate":"2019-12-24","paymentDate":"2019-12-31","value":0.3445,"currency":"USD"},{"executeDate":"2022-12-19","recordDate":"2022-12-20","paymentDate":"2022-12-23","value":0.19276,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"DBV\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"DBV\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2532883740","title":"DBV Technologies Is Maintained at Market Outperform by JMP Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=2532883740","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532883740?lang=en_us&edition=fundamental","pubTime":"2025-05-02 01:17","pubTimestamp":1746119820,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/DBVT/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 01, 2025 13:17 ET (17:17 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["JMP","DBV","DBVT"],"gpt_icon":0},{"id":"2532091449","title":"DBV Technologies Q1 EPS $(0.26) Up From $(0.28) YoY","url":"https://stock-news.laohu8.com/highlight/detail?id=2532091449","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532091449?lang=en_us&edition=fundamental","pubTime":"2025-05-01 05:08","pubTimestamp":1746047320,"startTime":"0","endTime":"0","summary":"DBV Technologies (NASDAQ:DBVT) reported quarterly losses of $(0.26) per share. This is a 7.14 percent increase over losses of $(0.28) per share from the same period last year.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/04/45120377/dbv-technologies-q1-eps-0-26-up-from-0-28-yoy","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DBV","DBVT"],"gpt_icon":0},{"id":"2532095314","title":"DBV Technologies Reports First Quarter 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2532095314","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532095314?lang=en_us&edition=fundamental","pubTime":"2025-05-01 04:00","pubTimestamp":1746043200,"startTime":"0","endTime":"0","summary":"DBV Technologies , a clinical-stage biopharmaceutical company, today reported financial results for the First Quarter of 2025. The quarterly and three months financial statements were approved by the Board of Directors on April 30, 2025.The Company’s interim condensed consolidated financial statements for the three months ended March 31, 2025, are prepared in accordance with accounting principles generally accepted in the United States .Our Condensed Consolidated Financial Statements have been prepared assuming the Company will continue as a going concern. The going concern assumption contemplates the realization of assets and satisfaction of liabilities in the normal course of business.Cash and cash equivalents amounted to $13.0 million as of March 31, 2025, compared to $32.5 million as of December 31, 2024, a net decrease of $19.5 million. This decrease includes $19.7 million of cash used in operating activities, mainly in external clinical trial related expenses, notably progress on","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/dbv-technologies-reports-first-quarter-200000986.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["DBV","DBVTF","BK4139","DBVT"],"gpt_icon":0},{"id":"2531087308","title":"Why DBV Technologies S.A. (DBVT) is Surging in 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2531087308","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531087308?lang=en_us&edition=fundamental","pubTime":"2025-04-30 18:25","pubTimestamp":1746008705,"startTime":"0","endTime":"0","summary":"After lagging behind the broader market in 2024, many healthcare stocks are making a comeback this year. Healthcare spending has been continuously soaring and is projected to do so in the coming years due to demographic tailwinds. The industry now accounts for a fifth of the U.S. economy, and it’s a good idea to have exposure to it.Most executives now hold a favorable view of the industry’s prospects, a notable increase from 52% just a year ago. Moreover, it’s an industry that is more insulated from tariffs and macro risks.Of course, the top gainers here are not defensive healthcare stocks, but it’s still worth looking into the winners here if you are chasing potential multibaggers.DBV Technologies S.A.  is a clinical-stage biopharmaceutical company developing non-invasive, self-administered therapies for food allergies, most notably the Viaskin Peanut Patch for children.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/why-dbv-technologies-dbvt-surging-102505047.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":[".IXIC","PSQ","USAW.SI","DBVTF","QLD","BK4139","DBV","QID","DBVT","USJW.SI","SQQQ","NQmain","NVIW.SI","MNQmain","TQQQ","TSYW.SI"],"gpt_icon":1},{"id":"2526971641","title":"DBV Technologies announces filing of 2024 Annual Report on Form 10-K and Universal Registration Document","url":"https://stock-news.laohu8.com/highlight/detail?id=2526971641","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526971641?lang=en_us&edition=fundamental","pubTime":"2025-04-12 04:30","pubTimestamp":1744403400,"startTime":"0","endTime":"0","summary":"DBV Technologies , a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need , today announced:. The audited financial statements for the year ended December 31, 2024 were approved by the Board of Directors on April 11, 2025, and present no changes from the unaudited financial statements examined by the Board of Directors on March 23 and published in the Company's press release dated March 24, 2025;The filing, for the year ended December 31, 2024, of its Annual Report on Form 10-K with the U.S. Securities and Exchange Commission  and its Universal Registration Document  with the French market authority, “Autorité des Marchés Financiers” .DBV Technologies is headquartered in Chtillon, France, with North American operations in Warren, NJ. The Company’s ord","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/dbv-technologies-announces-filing-2024-203000907.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["UVV","DBV","DBVT","BK4139","BK4075","DBVTF"],"gpt_icon":0},{"id":"2524890603","title":"DBV Technologies Delays 10-K Filing Amid Financing Efforts","url":"https://stock-news.laohu8.com/highlight/detail?id=2524890603","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524890603?lang=en_us&edition=fundamental","pubTime":"2025-04-01 06:34","pubTimestamp":1743460481,"startTime":"0","endTime":"0","summary":"DBV Technologies SA – American ( ($DBVT) ) has released a notification of late filing. DBV Technologies SA – American has announced a delay in fili...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/dbv-technologies-delays-10-k-filing-amid-financing-efforts?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/dbv-technologies-delays-10-k-filing-amid-financing-efforts?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["DBV"],"gpt_icon":0},{"id":"2524977206","title":"DBV Technologies Secures $306.9M for Viaskin Peanut Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2524977206","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524977206?lang=en_us&edition=fundamental","pubTime":"2025-04-01 04:38","pubTimestamp":1743453513,"startTime":"0","endTime":"0","summary":"DBV Technologies SA – American ( ($DBVT) ) has shared an announcement. On March 27, 2025, DBV Technologies announced a private placement agreement ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/dbv-technologies-secures-306-9m-for-viaskin-peanut-program?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/dbv-technologies-secures-306-9m-for-viaskin-peanut-program?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["DBV"],"gpt_icon":0},{"id":"2522198501","title":"DBV Technologies ADRs Rise After Up to $306.9M in New Financing","url":"https://stock-news.laohu8.com/highlight/detail?id=2522198501","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522198501?lang=en_us&edition=fundamental","pubTime":"2025-03-28 23:09","pubTimestamp":1743174540,"startTime":"0","endTime":"0","summary":"American depositary receipts of DBV Technologies gained after the company reported new financing of up to $306.9 million.The biopharmaceutical company's ADRs were up 57%, at $6.14, Friday morning. They have risen about 99% since the beginning of the year.Earlier in the week, DBV Technologies, which is developing the Viaskin patch for the treatment of pediatric peanut allergy, said its cash would likely run out after next month, casting doubt about its ability to continue as a going concern.The new money--which includes proceeds of $125.5 million to be received upon closing, and up to $181.4 million if all the warrants are exercised--tied to specific conditions, such as DBV's Phase 3 study hitting its primary endpoint.The Montrouge, France, company expects that the proceeds would be used for working capital and general corporate purposes, to finance the continued development of the Viaskin Peanut program, to finance the preparation and submission of a potential Biologics License Applica","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DBV","BK4139","DBVT"],"gpt_icon":0},{"id":"2522478345","title":"DBV Technologies Unveils Peanut Allergy Patch Funding of Up to $306.9 Million; Shares Jump Premarket","url":"https://stock-news.laohu8.com/highlight/detail?id=2522478345","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522478345?lang=en_us&edition=fundamental","pubTime":"2025-03-28 17:20","pubTimestamp":1743153625,"startTime":"0","endTime":"0","summary":"DBV Technologies  late Thursday disclosed financing of up to $306.9 million to fund a peanut allergy patch for children aged four to seven years old.DBV shares soared nearly 50% in premarket activity Friday.The financing to be received includes gross proceeds of $125.5 million upon closing and up to $181.4 million if all the warrants in the sale are exercised, the company developing the Viaskin peanut patch to treat pediatric peanut allergy said.DBV expects to use the proceeds to fund the Viaskin Peanut program, prepare and submit a potential biologics license application, and finance the readiness of a launch of Viaskin in the US, if approved by the US Food and Drug Administration.The funding will result in an immediate dilution of more than 22% and a maximal dilution of up to almost 74% if all the warrants in its offering are fully exercised. The company said the VITESSE phase 3 study hitting its primary endpoint will trigger an acceleration of the exercise period of some of the warr","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["DBVT","DBV","BK4139"],"gpt_icon":0},{"id":"2522256217","title":"DBV Technologies Announces Financing of up to $306.9 Million (€284.5 Million) to Advance Viaskin® Peanut Patch Through Biologics License Application Submission and U.S. Commercial Launch, if Approved","url":"https://stock-news.laohu8.com/highlight/detail?id=2522256217","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522256217?lang=en_us&edition=fundamental","pubTime":"2025-03-28 10:30","pubTimestamp":1743129000,"startTime":"0","endTime":"0","summary":"DBV Technologies Announces Financing of up to $306.9 Million  to Advance Viaskin Peanut Patch Through Biologics License Application Submission and U.S. Commercial Launch, if Approved. DBV sufficiently funded through the expected Biologics License Application  submission to Food and Drug Administration  for the Viaskin peanut patch in children 4 – 7-years-old and commercial launch, if approved. “DBV is developing the Viaskin peanut patch for the treatment of pediatric peanut allergy. This injection of capital is coming on the heels of news issued earlier this week announcing alignment with the FDA on safety exposure data required for a BLA for Viaskin peanut patch in 4 – 7-year-olds, accelerating the timeline for a BLA filing submission upon potential successful completion of VITESSE,” said Daniel Tassé, Chief Executive Officer, DBV Technologies. “I wish to again thank the FDA for their engagement and quick response. We are thrilled that this significant transaction will support our tra","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/dbv-technologies-announces-financing-306-023000006.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["DBV","DBVT","DBVTF","BK4139","USA","BK4156"],"gpt_icon":1},{"id":"2522772087","title":"DBV Technologies Shares Fall After 2024 Loss Widens","url":"https://stock-news.laohu8.com/highlight/detail?id=2522772087","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522772087?lang=en_us&edition=fundamental","pubTime":"2025-03-25 00:30","pubTimestamp":1742833850,"startTime":"0","endTime":"0","summary":"DBV Technologies  shares fell 1.5% in recent Monday trading after the company reported that full-year 2024 losses widened to $1.17 per diluted share from $0.76 a year earlier.A single analyst polled by FactSet expected a loss of $0.98.As expected, no revenue for the year ended Dec. 31 was reported.As of Dec. 31, the company said it had $32.5 million in cash and cash equivalents, and expected it could fund operations through April.The company also announced the US Food and Drug Administration agreed with its proposal to consider the safety exposure data from the Vitesse Phase 3 study for Viaskin peanut patch in children aged four to seven years for a biologics license application filing in this age group.This expedites the submission of the application to H1 2026 and accelerates the potential launch of the product by a year if approved. The FDA's decision also eliminates the need to conduct the Comfort Children supplemental safety study, the company said.Price: 4.54, Change: -0.07, Perc","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["DBVT","DBV","BK4139"],"gpt_icon":0},{"id":"2521747032","title":"DBV's ADRs Fall After Going-Concern Warning as Cash Dries Up","url":"https://stock-news.laohu8.com/highlight/detail?id=2521747032","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521747032?lang=en_us&edition=fundamental","pubTime":"2025-03-24 20:11","pubTimestamp":1742818260,"startTime":"0","endTime":"0","summary":"DBV Technologies' American depositary receipts fell after the company said its cash would likely run out after next month.The stock was down 10% at $4.48 in premarket trading on Monday. Shares had gained 61% year-to-date through Friday's close, though they were trading up at $7.96 this time a year ago.The clinical-stage biopharmaceutical company disclosed overnight that it has substantial doubt about its ability to continue as a going concern.DBV said it has incurred operating losses and negative cash flows from operations since the company started, and that there currently isn't enough available cash and cash equivalents to support its operating plan for the next 12 months.The company expects that its current cash load would only be enough to fund operations into April. DBV is seeking additional capital for R&D efforts, but can't guarantee that it will get enough financing to meet its needs, or financing with attractive terms and conditions.DBV said it may have to scale back operation","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DBVT","BK4139","DBV"],"gpt_icon":0},{"id":"2521795133","title":"DBV Technologies' Peanut Allergy Patch Clears FDA Safety Hurdle for Children","url":"https://stock-news.laohu8.com/highlight/detail?id=2521795133","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521795133?lang=en_us&edition=fundamental","pubTime":"2025-03-24 16:20","pubTimestamp":1742804425,"startTime":"0","endTime":"0","summary":"DBV Technologies  said Monday the US Food and Drug Administration has agreed with the company's proposal that the safety exposure data from the its phase 3 study for Viaskin peanut patch in four- to seven-year-olds will be enough to support a biologics license application filing in this age group.The company plans to submit the application for the food allergies patch in H1 2026, potentially accelerating the product launch by about one year.DBV said it had cash and cash equivalents of $32.5 million as of the end of 2024, likely not enough to support its operating plan for the next 12 months. As such, it said there's \"substantial doubt\" about its ability to continue as a going concern.The company said it is actively reviewing potential financing and strategic options with its financial advisers.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["DBVT","BK4139","DBV"],"gpt_icon":0},{"id":"2521757765","title":"DBV Technologies Secures Agreement with FDA on Safety Exposure Data Required for BLA for Viaskin® Peanut Patch in 4–7-year-olds, Accelerating the Timeline for a BLA Filing Submission to 1H 2026, & Reports 2024 Unaudited Financial Results...","url":"https://stock-news.laohu8.com/highlight/detail?id=2521757765","media":"GlobeNewswire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521757765?lang=en_us&edition=fundamental","pubTime":"2025-03-24 14:30","pubTimestamp":1742797800,"startTime":"0","endTime":"0","summary":"DBV Technologies Secures Agreement with FDA on Safety Exposure Data Required for Biologics License Application  for Viaskin Peanut Patch in 4 – 7-year-olds, Accelerating the Timeline for a BLA Filing Submission to 1H 2026, and Reports 2024 Unaudited Financial Results1. COMFORT Children supplemental safety study in children 4 – 7-years-old no longer required. FDA confirms safety exposure data generated from VITESSE Phase 3 clinical study and VITESSE Open-Label Extension  are sufficient to support a Biologics License Application  for Viaskin peanut patch in children 4 – 7-years-old. “DBV’s alignment with FDA represents a tremendous achievement for food allergy families, clinicians, researchers, and countless external partners that have been working for many years to advance the Viaskin peanut patch in children living with peanut allergy,” said Daniel Tassé, Chief Executive Officer, DBV Technologies. “I thank the FDA and the Review Team for their collaboration and constructive approach du","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/dbv-technologies-secures-agreement-fda-063000471.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["DBVT","DBVTF","DBV"],"gpt_icon":0},{"id":"2516338674","title":"DBV Technologies Price Target Maintained With a $10.00/Share by Citizens Capital Markets","url":"https://stock-news.laohu8.com/highlight/detail?id=2516338674","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516338674?lang=en_us&edition=fundamental","pubTime":"2025-03-04 22:07","pubTimestamp":1741097220,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/DBVT/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 04, 2025 09:07 ET (14:07 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DBVT","DBV"],"gpt_icon":0},{"id":"2514304170","title":"DBV Technologies to Participate in Upcoming AAAAI/WAO Joint Congress","url":"https://stock-news.laohu8.com/highlight/detail?id=2514304170","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514304170?lang=en_us&edition=fundamental","pubTime":"2025-02-26 05:01","pubTimestamp":1740517260,"startTime":"0","endTime":"0","summary":"Chtillon, France, February 25, 2025 DBV Technologies to Participate in Upcoming AAAAI/WAO Joint Congress DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-s","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/02/25/3032411/0/en/DBV-Technologies-to-Participate-in-Upcoming-AAAAI-WAO-Joint-Congress.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2346227817.USD","BK4208","BK4585","LU0170899867.USD","ED","DBV","JYNT","BK4588","BK4185"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":2,"totalSize":36,"code":"91000000","status":"200"}]}}